NCT04269642 - SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2020

Primary Completion Date

September 29, 2021

Study Completion Date

December 31, 2021

Conditions

Early Parkinson's Disease

Interventions

DRUG

PT320 2.0mg Placebo

DRUG

PT320 2.0 mg

Exenatide slowly released formulation

DRUG

PT320 2.5 mg

Exenatide slowly released formulation

Trial Locations (5)

Seoul National University Bundang Hospital, Seongnam-si

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul

Seoul National University Hospital, Seoul